Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.
about
Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancerThe Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer TherapyCardio-oncology: Concepts and practicePrevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprololMyocardial strain imaging: how useful is it in clinical decision making?Cardiac toxicity in cancer survivorsOverview and management of cardiac adverse events associated with tyrosine kinase inhibitorsEvaluation and management of patients with heart disease and cancer: cardio-oncologyThe prevention, detection and management of cancer treatment-induced cardiotoxicity: a meta-reviewTherapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinomaCardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and ManagementCardiac risk in the treatment of breast cancer: assessment and management.Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic DrugsMyocardial creatine levels do not influence response to acute oxidative stress in isolated perfused heartMedical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.Cancer treatment-related cardiac toxicity: prevention, assessment and management.Strain imaging to detect cancer therapeutics-related cardiac dysfunction: are we there yet?Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.Subclinical ventricular dysfunction detected by speckle tracking two years after use of anthracycline.Cardiac complications of chemotherapy: role of imaging.Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies.Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs.Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage.Assessing the Cardiac Toxicity of Chemotherapeutic Agents: Role of Echocardiography.Heart failure following cancer treatment: characteristics, survival and mortality of a linked health data analysis.Diagnostic Strategies for Early Recognition of Cancer Therapeutics-Related Cardiac Dysfunction.Late effects of blood and marrow transplantation.Anthracycline induced cardiotoxicity: biomarkers and "Omics" technology in the era of patient specific care.Cardio-oncology: what you need to know now for clinical practice and echocardiography.Early Detection and Serial Monitoring of Anthracycline-Induced Cardiotoxicity Using T1-mapping Cardiac Magnetic Resonance Imaging: An Animal Study.Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives.Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure.Assessment of cardiotoxicity with cardiac biomarkers in cancer patients.Hospital-level variation in use of cardiovascular testing for adults with incident heart failure: findings from the cardiovascular research network heart failure study.Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab.Safety and efficacy of aerobic training in patients with cancer who have heart failure: an analysis of the HF-ACTION randomized trial2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by represMechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?Chemotherapy-induced cardiotoxicity.Stem cell therapy and breast cancer treatment: review of stem cell research and potential therapeutic impact against cardiotoxicities due to breast cancer treatment.
P2860
Q24234511-022D9204-897A-4DA4-A309-080FF1301D93Q26743433-A9561796-EAFB-4455-92B4-F85A1889AA09Q26750878-6D4E6E79-4793-4488-817B-031E9DBA81B7Q26768272-618E834E-7C2A-4948-94C6-DBD4652439F2Q26778343-3B9BD7BD-7B6D-4BA8-8C51-900243546D0AQ26851957-C57A3691-6C4B-4ECA-8B10-11B62A6571F6Q26865766-3A630C1A-FC92-478D-88AB-84AC693F0C4EQ26998273-91838E8E-AF95-4D2C-8008-21995128CC09Q27010466-15FAAE18-3477-4DD7-855B-3F5935D27C75Q27013665-2CEEF882-E2E7-4478-86B1-B363C38005BAQ28068290-59C7C0DE-9FF8-4440-8B36-B212FF203A3AQ28081385-45604455-8304-4299-856B-E7AFC71AAC5AQ28087776-BE86DBF2-FF1F-47EF-980B-41CACCD83D4CQ28543466-ACE6CCCC-4EA6-49EE-8233-88DF0FCE8A47Q30248340-BA9A4F2C-2E06-4CC6-AA74-850EC361429CQ30276456-DC0B3154-9E04-4FEA-AFEF-D31C1C2D1011Q30385954-F7A9ACD0-C756-429A-A8EF-409FBDCF925BQ30401812-34FAC095-2A85-4086-983C-C16304E24E2DQ30412756-7FE524AC-6599-4577-BE62-F4108A410782Q30415201-F955A946-617A-4A34-A0F4-23942B3CD590Q30426853-7E09A0F1-1858-4BC1-8368-B28E639C851AQ30427656-5723CFA9-F814-4541-9C94-8B5800F2464AQ30439608-5E111E74-E83C-4A4D-8B8A-9DC51AE8ABCCQ30446509-12F8279F-FAAD-4939-930F-E6DEF692DFF6Q31120288-D53ABD39-450D-46E0-B230-52F0218B3945Q33565936-CE1E6077-B660-49B2-A89C-6966D82D1321Q33574136-C3B9B47B-ABB8-4DA1-A260-03C750CA8548Q33658456-F9BDDA31-0FEF-44AC-9A5A-A2F0B3DC8195Q33701308-5DDA05A2-C4C1-4D0E-A00E-56CD36322A5AQ33752979-BAB0EB45-AF46-4518-8298-A83A51667A90Q33807542-C1A975EA-134D-4F7B-9E31-C61EC551ACC4Q33815037-7E616353-62AB-439F-9CC9-EF1C97C71724Q33896047-3D9709AD-7E46-4192-B6B8-BECD61B03F70Q33922644-017B2EF9-53AE-4EE8-8BD9-C181E987E883Q33930241-FCD45BF2-BAAF-4059-8E43-070D35B5E128Q34001004-6808C01B-5521-49A5-9403-A749B975BC24Q34046881-B71ECE3B-620E-43D5-9252-C90450F3BED8Q34102834-FB859BAF-EE15-460F-85FF-8919A8094191Q34258080-5637700E-05EB-4991-B1C2-C81EC8AA97A3Q34441749-A1E5D0CA-EC52-4052-A597-69D500B39DEA
P2860
Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Anthracycline-induced cardiomy ...... onse to pharmacologic therapy.
@ast
Anthracycline-induced cardiomy ...... onse to pharmacologic therapy.
@en
Anthracycline-induced cardiomy ...... onse to pharmacologic therapy.
@nl
type
label
Anthracycline-induced cardiomy ...... onse to pharmacologic therapy.
@ast
Anthracycline-induced cardiomy ...... onse to pharmacologic therapy.
@en
Anthracycline-induced cardiomy ...... onse to pharmacologic therapy.
@nl
prefLabel
Anthracycline-induced cardiomy ...... onse to pharmacologic therapy.
@ast
Anthracycline-induced cardiomy ...... onse to pharmacologic therapy.
@en
Anthracycline-induced cardiomy ...... onse to pharmacologic therapy.
@nl
P2093
P1476
Anthracycline-induced cardiomy ...... onse to pharmacologic therapy.
@en
P2093
Alessandro Colombo
Carlo M Cipolla
Cesare Fiorentini
Daniela Cardinale
Fabrizio Veglia
Gaia De Giacomi
Giuseppina Lamantia
Maurizio Civelli
Nicola Colombo
P304
P356
10.1016/J.JACC.2009.03.095
P407
P50
P577
2010-01-01T00:00:00Z